NASDAQ : ASMB
Assembly Biosciences, Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 20.13 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 409.86M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 409.86M |
| Enterprise Value | 91.85M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 13, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 20.36M |
| Shares Outstanding | 20.36M |
| Shares Change (YoY) | +133.27% |
| Shares Change (QoQ) | +11.56% |
| Owned by Insiders (%) | 3.02% |
| Owned by Institutions (%) | 41.75% |
| Float | 9.17M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 5.48 |
| Forward PS | 7.54 |
| PB Ratio | 1.31 |
| P/TBV Ratio | 1.34 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | 1.23 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 13.99 |
| Quick Ratio | 13.79 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -0.03% |
| Return on Assets (ROA) | -2.67% |
| Return on Invested Capital (ROIC) | -3.34% |
| Return on Capital Employed (ROCE) | -2.86% |
| Weighted Average Cost of Capital (WACC) | 10.55% |
| Revenue Per Employee | $1.03M |
| Profits Per Employee | -$575 |
| Employee Count | 73 |
| Asset Turnover | 0.36 |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 1.16 |
| 52-Week Price Change | -35.04% |
| 50-Day Moving Average | 26.14 |
| 200-Day Moving Average | 27.20 |
| Relative Strength Index (RSI) | 35.86 |
| Average Volume (20 Days) | 209,123 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 2.91M |
| Short Previous Month | 2.82M |
| Short % of Shares Out | 14.31% |
| Short % of Float | 31.76% |
| Short Ratio (days to cover) | 8.29 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 74.85M |
| Gross Profit | 11.19M |
| Operating Income | -8.80M |
| Pretax Income | -42,000 |
| Net Income | -42,000 |
| EBITDA | -8.69M |
| EBIT | -8.80M |
| Loss Per Share | -$0.00 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 320.36M |
| Total Debt | 2.35M |
| Net Cash | 318.01M |
| Net Cash Per Share | $15.62 |
| Equity (Book Value) | 305.65M |
| Book Value Per Share | 15.40 |
| Working Capital | 304.53M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -38.48M |
| Capital Expenditures | -85,000 |
| Depreciation & Amortization | 110,000 |
| Net Borrowing | n/a |
| Free Cash Flow | -38.57M |
| FCF Per Share | -$1.89 |
Margins
| Measure | Value |
|---|
| Gross Margin | 14.95% |
| Operating Margin | -11.75% |
| Pretax Margin | -0.06% |
| Profit Margin | -0.06% |
| EBITDA Margin | -11.61% |
| EBIT Margin | -11.75% |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -133.27% |
| Shareholder Yield | -133.27% |
| Earnings Yield | -0.01% |
| FCF Yield | -9.41% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $52.00 |
| Price Target Difference | 158.32% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 5 |
| Revenue Growth Forecast (3Y) | -12.30% |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | Feb 12, 2024 |
| Split Type | Reverse |
| Split Ratio | 1:12 |
Scores
| Measure | Value |
|---|
| Altman Z-Score | 7.79 |
| Piotroski F-Score | 3 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |